Avalo 制药

最新新闻

• Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/4/9
• 评级变动
  BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $58
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Citizens JMP Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Stifel Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• 评级变动
  Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/3/30
• 评级变动
  A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• Guggenheim Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Cuts Target Price to $48
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Citizens JMP Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/4/6
• 评级变动
  TD Cowen Maintains Avalo Therapeutics(AVTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $30 to $58
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 公司公告
  Avalo Therapeutics: Avalo Therapeutics, Inc. - Reverse Split Option Symbol: AVTX New Symbol: AVTX1
  OCC · 2022/7/7
• BofA Securities Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Guggenheim Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/5/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。